Phase 1 evaluation of APN401, an autologous CBL-B-silenced PBMC therapy, in advanced solid tumors
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: T cells, induction of cytotoxic mediators, and expansion of dominant T cell receptor β (TCRβ) clonotypes. These changes were most pronounced in patients with stable disease but remain exploratory and hypothesis-generating. These findings support further evaluation of APN401 in larger, controlled studies.
Source: Molecular Therapy Oncology
Authors: Alexander Dohnal, Nina Worel, Thomas Bogenrieder, Thorsten Fuereder, Martin Burian, Dominik Wolf, Gerald Prager, Richard Greil, Anja Peterbauer-Scherb, Beate Schrenk, Stefan Bunka, Ernesto Abila, Felix Batrina, Maria Urban, Julia Buchberger, Alice Schwarzboeck, Bernhard Peball, Sandra Seidl, Hannes Muehleisen, Stefan Stranner, Mario Kuttke, Angela Halfmann, Sarah Bischof, Andreas Birbach, Romana Gugenberger
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7220400638